CoChat

PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p

Open access
Audrito, Valentina, Serra, Sara, Stingi, Aureliano, Orso, Francesca, Gaudino, Federica, Bologna, Cinzia, Neri, Francesco, Garaffo, Giulia, Nassini, Romina, Baroni, Gianna, Rulli, Eliana, Massi, Daniela, Oliviero, Salvatore, Piva, Roberto, Taverna, Daniela, Mandalà, Mario, Deaglio, Silvia · 2017 · Oncotarget
Cited by 118

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

// Valentina Audrito 1, 2, * , Sara Serra 1, 2, * , Aureliano Stingi 1, 2 , Francesca Orso 3 , Federica Gaudino 1, 2 , Cinzia Bologna 1, 2 , Francesco Neri 1 , Giulia Garaffo 3 , Romina Nassini 4 , Gianna Baroni 5 , Eliana Rulli 6 , Daniela Massi 5 , Salvatore Oliviero 1, 7 , Roberto Piva 3 , Daniela Taverna 3 , Mario Mandalà 8, ** , Silvia Deaglio 1, 2, ** 1 Human Genetics Foundation (HuGeF), Turin, Italy 2 Department of Medical Sciences, University of Turin, Turin, Italy 3 Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy 4 Department of Health Sciences, University of Florence, Italy 5 Department of Surgery and Translational Medicine, University of Florence, Italy 6 Methodology for Clinical Research Laboratory, IRCCS – Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy 7 Department of Life Sciences and Systems Biology, University of Turin, Turin, Italy 8 Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy * These authors have contributed equally to this work ** These authors have shared last authorship Correspondence to: Silvia Deaglio, email: silvia.deaglio@unito.it , silvia.deaglio@hugef-torino.org Keywords: melanoma, targeted therapy, resistance to therapy, microRNA, regulation of gene expression Received: August 11, 2016 Accepted: January 06, 2017 Published: February 09, 2017 ABSTRACT PD-L1 is expressed by a subset of patients with metastatic melanoma (MM) with an unfavorable outcome. Its expression is increased in cells resistant to BRAF or MEK inhibitors (BRAFi or MEKi). However, the function and regulation of expression of PD-L1 remain incompletely understood. After generating BRAFi- and MEKi-resistant cell lines, we observed marked up-regulation of PD-L1 expression. These cells were characterized by a common gene expression profile with up-regulation of genes involved in cell movement. Consistently, in vitro they showed significantly increased invasive properties. This phenotype was controlled in part by PD-L1, as determined after silencing the molecule. Up-regulation of PD-L1 was due to post-transcriptional events controlled by miR-17-5p, which showed an inverse correlation with PD-L1 mRNA. Direct binding between miR-17-5p and the 3’-UTR of PD-L1 mRNA was demonstrated using luciferase reporter assays. In a cohort of 80 BRAF-mutated MM patients treated with BRAFi or MEKi, constitutive expression of PD-L1 in the absence of immune infiltrate, defined the patient subset with the worst prognosis. Furthermore, PD-L1 expression increased in tissue biopsies after the metastatic lesions became resistant to BRAFi or MEKi. Lastly, plasmatic miR-17-5p levels were higher in patients with PD-L1 + than PD-L1 - lesions. In conclusion, our findings indicate that PD-L1 expression induces a more aggressive behavior in melanoma cells. We also show that PD-L1 up-regulation in BRAFi or MEKi-resistant cells is partly due to post-transcriptional mechanisms that involve miR-17-5p, suggesting that miR-17-5p may be used as a marker of PD-L1 expression by metastatic lesions and ultimately a predictor of responses to BRAFi or MEKi.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.15213

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 118

Metadata

Authors
Audrito, V., Serra, S., Stingi, A., Orso, F., Gaudino, F., Bologna, C., Neri, F., Garaffo, G., Nassini, R., Baroni, G., Rulli, E., Massi, D., Oliviero, S., Piva, R., Taverna, D., Mandalà, M., & Deaglio, S.
Venue
Oncotarget
Published
2017-02-09
Volume
8
Issue
9
Pages
15894-15911
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2588857004
Cited by
118
References
11
FWCI
6.25
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p. https://app.cochat.ai/papers/10.18632/oncotarget.15213
The paper
Audrito, V., Serra, S., Stingi, A., Orso, F., Gaudino, F., Bologna, C., Neri, F., Garaffo, G., Nassini, R., Baroni, G., Rulli, E., Massi, D., Oliviero, S., Piva, R., Taverna, D., Mandalà, M., & Deaglio, S. (2017). PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p. Oncotarget. https://doi.org/10.18632/oncotarget.15213

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.